PVLA (STOCKS)
Palvella Therapeutics, Inc. Common Stock
$129.000000
+1.880000 (+1.48%)
Prev close: $127.120000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Wesley H. Kaupinen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,846.61M
- Employees
- 14
- P/E (TTM)
- -34.80
- P/B (TTM)
- 56.24
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
15
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-1.07 | $-0.93 | -0.1413 | -15.20% |
|
Sep 2025 (Q3)
|
$-1.03 | $-0.86 | -0.1749 | -20.45% |
|
Jun 2025 (Q2)
|
$-0.86 | $-0.76 | -0.1044 | -13.82% |
|
Mar 2025 (Q1)
|
$-0.74 | $-1.24 | +0.4955 | +40.11% |
Financial Statements
| Revenues | $2.59M |
| Benefits Costs and Expenses | $44.31M |
| Costs And Expenses | $44.31M |
| Operating Expenses | $38.60M |
| Research and Development | $22.84M |
| Other Operating Expenses | $15.76M |
| Operating Income/Loss | -$38.60M |
| Income/Loss From Continuing Operations After Tax | -$41.72M |
| Income/Loss From Continuing Operations Before Tax | -$41.72M |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Current | $0.00 |
| Interest Income/Expense After Provision For Losses | $2.59M |
| Interest Income/Expense Operating, Net | $2.59M |
| Net Income/Loss | -$41.72M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$41.72M |
| Net Income/Loss Available To Common Stockholders, Basic | -$41.72M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$3.71 |
| Diluted Earnings Per Share | -$3.71 |
| Basic Average Shares | 11,251,250 |
| Diluted Average Shares | 11,251,250 |
| Assets | $59.56M |
| Current Assets | $58.99M |
| Noncurrent Assets | $572.00K |
| Liabilities | $31.58M |
| Current Liabilities | $11.34M |
| Accounts Payable | $4.60M |
| Wages | $1.92M |
| Other Current Liabilities | $4.83M |
| Noncurrent Liabilities | $20.23M |
| Equity | $27.98M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $27.98M |
| Liabilities And Equity | $59.56M |
| Net Cash Flow From Operating Activities | -$25.01M |
| Net Cash Flow From Operating Activities, Continuing | -$25.01M |
| Net Cash Flow From Investing Activities | $25.62M |
| Net Cash Flow From Investing Activities, Continuing | $25.67M |
| Net Cash Flow From Financing Activities | -$660.00K |
| Net Cash Flow From Financing Activities, Continuing | -$660.00K |
| Exchange Gains/Losses | $46.00K |
| Net Cash Flow | -$46.00K |
| Net Cash Flow, Continuing | -$92.00K |
| Comprehensive Income/Loss | -$41.64M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$41.64M |
| Other Comprehensive Income/Loss | -$41.64M |